Findings

What do systematic reviews say?

873 questions · 883 findings · 38 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 319 · 36.1%GRADE not reported 18 · 2%Very low 198 · 22.4%Low 186 · 21.1%Moderate 147 · 16.6%High 15 · 1.7%

Respiratory muscle training vs control

FEV1 % predicted · adults and children with cystic fibrosis

1 finding from 1 review

Respiratory muscle training for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 83 participants
Very low

Respiratory muscle training vs control

FVC · adults and children with cystic fibrosis

1 finding from 1 review

Respiratory muscle training for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 72 participants
Very low

Respiratory muscle training vs control

Exercise capacity · adults and children with cystic fibrosis

1 finding from 1 review

Respiratory muscle training for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 54 participants
Very low

Respiratory muscle training vs control

HRQoL: total score · adults and children with cystic fibrosis

1 finding from 1 review

Respiratory muscle training for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 69 participants
Very low

Respiratory muscle training vs control

Respiratory muscle function: maximal inspiratory pressure (PImax) · adults and children with cystic fibrosis

1 finding from 1 review

Respiratory muscle training for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 87 participants
Very low

Respiratory muscle training vs control

Respiratory muscle function: inspiratory capacity · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Respiratory muscle training for cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: monoclonal antibody KB001‐A vs placebo

Pulmonary exacerbations · children (12 or over) and adults with cystic fibrosis and lung infection

Summary of findings: monoclonal antibody KB001‐A showed no clear difference in pulmonary exacerbations compared with placebo (low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
RR 0.25 [0.03, 2.4]
2 studies · 196 participants
Low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Respiratory function number of episodes of a drop in FEV1 (unit of measurement not given) · children (12 or over) and adults with cystic fibrosis and lung infection

It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes respiratory function number of episodes of a drop in FEV1 (unit of… compared with placebo (very low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
RR 4.74 [0.28, 79.44]
2 studies · 196 participants
Very low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Number experiencing adverse effects · children (12 or over) and adults with cystic fibrosis and lung infection

It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes adverse events number of participants experiencing adverse events compared with placebo (very low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
RR 1.3 [0.9, 1.87]
2 studies · 196 participants
Very low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Need for antibiotics time to need for antibiotics · children (12 or over) and adults with cystic fibrosis and lung infection

Summary of findings: monoclonal antibody KB001‐A showed no clear difference in need for antibiotics time to need for antibiotics compared with placebo (moderate certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
HR 1 [0.69, 1.45]
1 study · 169 participants
Moderate

Summary of findings: monoclonal antibody KB001‐A vs placebo

QoL · children (12 or over) and adults with cystic fibrosis and lung infection

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Sputum microbiology · children (12 or over) and adults with cystic fibrosis and lung infection

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Inflammatory markers · children (12 or over) and adults with cystic fibrosis and lung infection

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 196 participants
Very low

Summary of findings: oral antioxidants (NAC/GSH) vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

2 findings from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 125 participants
Very low
Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 62 participants
Moderate

Summary of findings: oral antioxidants (NAC/GSH) vs placebo

Quality of life: change from baseline in CFQ‐R · adults and children with cystic fibrosis

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
Moderate

Summary of findings: oral antioxidants (NAC/GSH) vs placebo

Change in BMI · adults and children with cystic fibrosis

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 62 participants
Moderate

Summary of findings: oral antioxidants (NAC/GSH) vs placebo

Time to next exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: oral antioxidants (NAC/GSH) vs placebo

Adverse events · adults and children with cystic fibrosis

Summary of findings: oral antioxidants (NAC/GSH) showed no clear difference in adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
OR 2.92 [0.11, 74.05]
1 study · 70 participants
Moderate

Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy

Annualized joint Bleeding Rate (AjBR) · people with inhibitors

1 finding from 1 review

Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 57 participants
Moderate

Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy

QoL · people with inhibitors

1 finding from 1 review

Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 48 participants
Low